Endothelial cell expression patterns
To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
1. An isolated molecule selected from the group consisting of: an intact antibody, a single chain variable region (ScFv), a monoclonal antibody, Fab, Fab′, and Fab′2, wherein said molecule specifically binds to an extracellular domain of TEM 17 as shown in SEQ ID NO: 230.
2. The isolated molecule of claim 1 which is an intact antibody molecule.
3. The isolated molecule of claim 1 which is a single chain variable region (ScFv).
4. The isolated molecule of claim 1 which is a monoclonal antibody.
5. The isolated molecule of claim 1 which is a humanized antibody.
6. The isolated molecule of claim 1 which is a human antibody.
7. The isolated molecule of claim 1 which is bound to a cytotoxic moiety.
8. The isolated molecule of claim 1 which is bound to a therapeutic moiety.
9. The isolated molecule of claim 1 which is bound to a detectable moiety.
10. The isolated molecule of claim 1 which is bound to an anti-tumor agent.
11. The isolated molecule of claim 4 which is bound to a cytotoxic moiety.
12. The isolated molecule of claim 4 which is bound to a therapeutic moiety.
13. The isolated molecule of claim 4 which is bound to a detectable moiety.
14. The isolated molecule of claim 4 which is bound to an anti-tumor agent.
15. The isolated molecule of claim 6 which is bound to a cytotoxic moiety.
16. The isolated molecule of claim 6 which is bound to a therapeutic moiety.
17. The isolated molecule of claim 6 which is bound to a detectable moiety.
18. The isolated molecule of claim 6 which is bound to an anti-tumor agent.
19. The isolated molecule of claim 1 which specifically binds to residues 137-244 or 280-344 of TEM17.
20. The isolated molecule of claim 2 which specifically binds to residues 137-244 or 280-344 of TEM17.
21. The isolated molecule of claim 3 which specifically binds to residues 137-244 or 280-344 of TEM17.
22. The isolated molecule of claim 4 which specifically binds to residues 137-244 or 280-344 of TEM17.
23. The isolated molecule of claim 5 which specifically binds to residues 137-244 or 280-344 of TEM17.
24. The isolated molecule of claim 6 which specifically binds to residues 137-244 or 280-344 of TEM17.
25. The isolated molecule of claim 1 which specifically binds to residues 19-426 of TEM17.
26. The isolated molecule of claim 2 which specifically binds to residues 19-426 of TEM17.
27. The isolated molecule of claim 3 which specifically binds to residues 19-426 of TEM17.
28. The isolated molecule of claim 4 which specifically binds to residues 19-426 of TEM17.
29. The isolated molecule of claim 5 which specifically binds to residues 19-426 of TEM17.
30. The isolated molecule of claim 6 which specifically binds to residues 19-426 of TEM17.
31. The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 2 times more than to irrelevant antigen or antigen mixture.
32. The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 5 times more than to irrelevant antigen or antigen mixture.